Summary of COVID-19 AgNP studies

1. Almanza-Reyes et al., Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: In vitro and in vivo

231 patient AgNP prophylaxis RCT: 94% fewer cases (p<0.0001) and 49% improvement (p=0.003).
RCT 231 healthcare workers showing significantly lower COVID-19 infection rates with silver nanoparticle (AgNPs) oral and nasal rinses. Authors also report in vitro experiments showing dose-dependent inhibition in cell cultures.
Aug 2021, PLOS ONE, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0256401, https://c19p.org/almanzareyesagnp

2. Wieler et al., Reduction in the COVID-19 pneumonia case fatality rate by silver nanoparticles: A randomized case study

40 patient AgNP late treatment RCT: 56% lower mortality (p=0.01).
RCT 40 late stage hospitalized COVID-19 patients on oxygen showing significantly higher survival rates with intravenous silver nanoparticles (AgNPs). Authors suggest that antiviral, anti-inflammatory, antiplatelet, and antimicrobial properties may explain the observed benefits.
Mar 2023, Heliyon, https://www.sciencedirect.com/science/article/pii/S2405844023016262, https://c19p.org/wieleragnp